Phase 2 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People whose general health and ability to carry out daily activities falls within a certain range, as measured by a standard oncology scale called ECOG 0–3 (confirm with trial site)
- People who have been diagnosed with brain metastases (cancer that has spread to the brain) confirmed by imaging scans
- People who are scheduled to have surgery to remove at least one brain metastasis
- People who are planned to receive a targeted form of radiation therapy called stereotactic radiosurgery (SRS) after their surgery
- People of reproductive potential who are willing and able to use two reliable forms of contraception for at least 4 weeks before the screening stage, throughout the study, and for 1 week after the final imaging scan — acceptable methods include male condoms with spermicide, a diaphragm or cap with spermicide, a copper IUD, a hormonal IUD (such as Mirena®), implants, hormone injections, combined contraceptive pills, the mini-pill, or the contraceptive patch
- People who are postmenopausal (and therefore do not need contraception) — this includes those who have had no periods for 1 or more years after stopping hormone treatment, those with hormone levels confirmed in the postmenopausal range, those whose menopause was caused by radiation or chemotherapy with no period for more than 1 year, or those who have had surgical removal of both ovaries or a hysterectomy
Who may not be able to join:
- People who have previously had a severe allergic reaction (anaphylaxis) to the imaging agent 18F-Fluciclovine
- People who have evidence of cancer spreading along the lining of the brain or spinal cord (leptomeningeal disease)
- People who have previously received whole-brain radiation therapy
- People who are unable to have an MRI scan, for example due to having a pacemaker or another safety-related reason
- People who are pregnant at the time the imaging agent 18F-Fluciclovine is scheduled to be given
- People who are breastfeeding at the time of the imaging scan and are unwilling to stop breastfeeding for 24 hours after the scan (a temporary pause in breastfeeding for 24 hours after imaging is considered acceptable)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Rupesh R Kotecha, M.D., Miami Cancer Institute/Baptist Health South Florida
Phone: 17865962000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in conformality index of tumor target volume delineation; Change in PET scan standardized uptake value (SUV) parameters
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.